Immunotherapy for Non-Squamous NSCLC: Should We be Using Biomarker Selection?
The immune checkpoint inhibitor Opdivo (nivolumab) shows better efficacy than Taxotere (docetaxel) for advanced non-squamous NSCLC, but this was seen only in patients with PD-L1 protein expression on ...
Author: cancergrace
Added: 06/24/2015
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts